Upgrade to SI Premium - Free Trial

Cocrystal Pharma, Inc. (COCP)

1.00 -0.02 (1.96%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/17/26)

Latest Headlines

Form 8-K Cocrystal Pharma, Inc. For: Jun 03 June 9, 2026 7:00 AM - SEC Filing Form 4 Cocrystal Pharma, Inc. For: Jun 03 Filed by: SAPIRSTEIN JAMES June 3, 2026 4:11 PM - SEC Filing Form 3 Cocrystal Pharma, Inc. For: Jun 03 Filed by: SAPIRSTEIN JAMES June 3, 2026 4:10 PM - SEC Filing Cocrystal Pharma names James Sapirstein as chief executive officer June 3, 2026 7:03 AM - StreetInsider Form 8-K Cocrystal Pharma, Inc. For: Jun 03 June 3, 2026 7:00 AM - SEC Filing Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer June 3, 2026 7:00 AM - Globe NewsWire Form DEFA14A Cocrystal Pharma, Inc. May 27, 2026 4:32 PM - SEC Filing Form DEF 14A Cocrystal Pharma, Inc. For: May 27 May 27, 2026 4:31 PM - SEC Filing Form 8-K Cocrystal Pharma, Inc. For: May 26 May 26, 2026 8:30 AM - SEC Filing Cocrystal Pharma develops pan-viral inhibitors for hantavirus and influenza May 26, 2026 8:05 AM - StreetInsider Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza May 26, 2026 8:00 AM - StreetInsider Form 10-Q Cocrystal Pharma, Inc. For: Mar 31 May 15, 2026 8:31 AM - SEC Filing Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results May 15, 2026 8:00 AM - Globe NewsWire Form EFFECT Cocrystal Pharma, Inc. May 4, 2026 6:06 AM - SEC Filing Form 8-K Cocrystal Pharma, Inc. For: Apr 30 April 30, 2026 4:32 PM - SEC Filing Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection April 30, 2026 4:05 PM - StreetInsider Form S-3 Cocrystal Pharma, Inc. April 23, 2026 7:16 PM - SEC Filing Form 8-K Cocrystal Pharma, Inc. For: Apr 02 April 2, 2026 8:31 AM - SEC Filing Cocrystal Pharma gets FDA fast track status for norovirus drug CDI-988 April 2, 2026 8:00 AM - StreetInsider Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive April 2, 2026 8:00 AM - StreetInsider Form 10-K Cocrystal Pharma, Inc. For: Dec 31 March 31, 2026 8:31 AM - SEC Filing Form 8-K Cocrystal Pharma, Inc. For: Mar 31 March 31, 2026 8:30 AM - SEC Filing Cocrystal begins Phase 1b norovirus trial at Emory University March 31, 2026 8:05 AM - StreetInsider Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs March 31, 2026 8:00 AM - StreetInsider Form 8-K Cocrystal Pharma, Inc. For: Mar 10 March 13, 2026 4:31 PM - SEC Filing Full Article List